The National Agency for Food and Drug Administration and Control, NAFDAC, has warned the public about the recall of all ...

Lonza has entered into a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds ...

Lone Star has entered into a definitive agreement to acquire the Capsules and Health Ingredients division of Lonza Group. Lonza will retain a 40 percent equity position in the business.

According to the agency, both substances belong to a class of medicines known as phosphodiesterase (PDE-5) inhibitors.

Lone Star Funds ("Lone Star") today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients ("CHI") division of ...

A 2026 consumer warning report examining DentaBiome's oral postbiotic formula, how FabM acid-lock and 30-second kitchen ...

Lonza signed an agreement to divest its Capsules & Health Ingredients or CHI business to Lone Star Funds for an enterprise value of CHF 2.3 billion or US$3 billion. This ...

Using medical or recreational marijuana to ease symptoms of numerous mental health conditions doesn’t work, according to two ...

The National Agency for Food and Drugs Administration and Control has announced a voluntary recall of all lots of the male enhancement dietary supplement MR.7 SUPER 700000 capsules, citing serious ...

A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verific ...

March 6 (Reuters) - Lonza will sell its capsules and health ingredients business to private equity firm Lone Star Funds for an enterprise value of 2.3 billion Swiss francs ($3.0 billion), the Swiss ...

Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe. The FDA has accepted two separate marketing ...